A novel regulator of p53
A novel regulator of p53
批准号:
8109367
负责人:
VIMLA BAND
金额:
$25.28万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-08-15 至 2013-07-31
关键词:
AcetylationApoptosisBindingBiochemicalBiochemical PathwayCREB-binding proteinCancer BiologyCarcinogensCell Culture TechniquesCell Cycle ArrestCellsChemicalsComplexDNA Binding DomainDNA DamageDNA RepairDataDevelopmentDiagnosticEP300 geneFutureGene ExpressionGene ProteinsGene TargetingGenesGenomeGenotoxic StressHistone AcetylationHistonesHomologous GeneHumanIn VitroKnockout MiceLeadLinkMalignant NeoplasmsMammalian CellMediatingMissense MutationModelingMutationNatureOncogenicPCAF genePathway interactionsProtein p53ProteinsRecruitment ActivityRelative (related person)RoleSiteTP53 geneTestingTherapeuticTransactivationTranscription CoactivatorTranscriptional ActivationTransferaseTumor Suppressor GenesUltraviolet RaysYeastsbasehuman CREBBP proteinmutantnovelpreventpromoterprotein activationprotein complexresponsesmall hairpin RNAtranscription factortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The p53 tumor suppressor gene is inactivated by missense mutations or deletion in over half of all human cancers. Biochemically, p53 functions as a sequence-specific transcriptional activator to induce genes involved in DNA repair, cell cycle arrest and apoptosis in response to genotoxic stress. These responses are essential to prevent the emergence of cells with unstable genomes, which are prone to oncogenic transformation. Thus, transactivation of specific genes is critical for p53 function. Coactivator complexes which link transcriptional activators, bound to specific promoters, to histone acetylation and basal transcriptional machinery, are essential for the function by sequence-specific transcription factors. We have identified the human ADA3 (alteration/deficiency in activation) protein as a novel p53-binding partner. In the yeast, ADAS is an essential component of the ADA coactivator complex that include ADA2 and GCN5 (general control non-repressed 5), a histone acetyl transferase (HAT). Only recent studies by us and others have begun to characterize the mammalian ADA complexes. We have demonstrated that ADAS directly interacts with p53 and enhances its transactivation function by promoting its acetylation and stability. shRNA-mediated knockdown of ADAS indicates that it is required for p53 acetylation and stabilization upon DNA damage. Mutant p53 that can not be acetylated on major p3OO acetylation sites is not stabilized by ADAS. Collectively, these findings lead us to hypothesize that hADAS is a central coactivator component that recruits p3OO/CBP and other HATs to acetylate and stabilize p53 on its target gene promoters leading to enhancement of p53-mediated function. Together, ADA3-dependent histone and p53 acetylation provide critical mechanisms for p53-mediated DNA damage response. To test these hypotheses, we will examine the role of ADAS in the recruitment of major HAT proteins (p3OO/CBP, hGCNS and PCAF) to p53. Furthermore, we will define the relative role of ADAS in p53-mediated cellular responses upon DNA damage (UV. radiation and chemicals) using cell culture models and ADAS conditional knockout mice (for UV and carcinogen-induced tumorigenesis) that we have generated. These analyses are likely to define a novel biochemical pathway to regulate p53-mediated cellular responses following genotoxic stress, and the relevance of the pathway as a barrier to oncogenic transformation. Elucidation of the role of this new biochemical pathway and definition of its components is likely to provide new targets for future development of gene- and protein-based diagnostic and therapeutic strategies for human cancer.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0075907
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Mukhopadhyay C, Zhao X, Maroni D, Band V, Naramura M]
通讯作者:
Naramura M
Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer
-
批准号:10474522
-
项目类别:
-
资助金额:$7.68万
-
财政年份:2021
-
负责人:VIMLA BAND
-
依托单位:
Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer
-
批准号:10294847
-
项目类别:
-
资助金额:$7.65万
-
财政年份:2021
-
负责人:VIMLA BAND
-
依托单位:
Ecdysoneless, A Novel Regulator of Androgen Receptor
-
批准号:9809834
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2019
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8775947
-
项目类别:
-
资助金额:$4.94万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8616349
-
项目类别:
-
资助金额:$29.89万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8448016
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8825337
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8115725
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8231335
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7554732
-
项目类别:
-
资助金额:$20.14万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7323606
-
项目类别:
-
资助金额:$6.9万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:7086808
-
项目类别:
-
资助金额:$23.32万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53 function
-
批准号:6521549
-
项目类别:
-
资助金额:$28.81万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53 function
-
批准号:6803610
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7892414
-
项目类别:
-
资助金额:$26.06万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:6548000
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:7554861
-
项目类别:
-
资助金额:$9.7万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:6916532
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53 function
-
批准号:6647144
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7491822
-
项目类别:
-
资助金额:$25.31万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: